Zealand Pharma A/S (ZEAL) Earnings Call Transcripts

Zealand Pharma A/S's Latest Earnings Call - June 9, 2026

In the second quarter of fiscal year 2026, Zealand Pharma A/S reported a strong performance driven by advancements in its obesity treatment pipeline, particularly with servalotide. The company highlighted significant data presented at the ADA conference, which emphasized the metabolic benefits of their therapies, although some concerns were raised regarding tolerability and discontinuation rates. Management maintained a positive outlook, signaling confidence in their product development strategies and the potential for future growth, particularly in the obesity market.

Reported metrics

Guidance from management

Management maintained a positive outlook for the upcoming quarters, emphasizing their commitment to flexible titration protocols and continued investment in research and development. They expect to initiate Phase III trials in the second half of the year.

What management said

So we have not committed to that. And in the honor of the partnership, I will not be more, you're going to say, clear on time lines, except to say that we are as companies hyper-focused on speed to market and then, of course, continue to invest to expand the label.

It's, of course, making sure, number one, and it's, of course, focusing on recruitment, but still making sure we get the right patients enrolled from the right centers and then it's focused on getting to market with a enough to get to market and then expand the label from there. So -- and.

What analysts pressed on

Analysts expressed concerns regarding the higher-than-expected dropout rates in servalotide trials and the implications for future patient retention. There were also questions about how the competitive landscape, particularly with Lilly's advancements, might impact Zealand's market position.

Main topics on the call

• ADA Conference Insights — Management expressed optimism about the data presented at the ADA conference, stating, "I was actually very pleased with the profile" of servalotide and its focus on metabolic health. However, there were concerns regardi...
• Titration Protocol Adjustments — Management acknowledged that the strict titration protocol in the servalotide trials led to higher dropout rates, stating, "that was a little bit of a surprise to me." They are now implementing more flexible titration st...
• Market Positioning of Servalotide — The company is positioning servalotide as a first-line therapy for obesity, focusing on metabolic health rather than just weight loss. Adam Steensberg noted, "It's really a product that speaks directly into the metabolic...
• Phase III Study Expectations — Management is focused on launching Phase III studies for both servalotide and its combination therapy, with expectations for double-digit weight loss and improved tolerability. They emphasized the importance of a tolerab...

Read the full Zealand Pharma A/S transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 51 Zealand Pharma A/S earnings call transcripts on record, spanning February 10, 2020 to June 9, 2026. Based on this history, Zealand Pharma A/S reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ZEAL

Exchange

CPSE

Country

DK

Sector

Health Care

Industry

Biotechnology

Calls on record

51

First call

February 10, 2020

Most recent

June 9, 2026

Reporting cadence

quarterly